TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Platelet Reactivity After TAVI: A Multicenter Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~For inclusion in the study subjects should fulfill the following criteria:~1. Provision of informed consent prior to any study specific procedures.~2. Adult patients (more than 18 years) with ability to understand and accept the participation in the clinical trial.~3. Patients with degenerative symptomatic severe AS accepted for TAVI after evaluation of the Heart Team of each center.~4. Patients who are not participating in any other clinical trial or research study (registries allowed).~Exclusion Criteria:~Subjects should not enter the study if any of the following exclusion criteria are fulfilled:~1. Recent stroke \<14 days prior to TAVI, non-revascularized severe coronary or carotid artery disease (\>70% stenosis) or life expectancy \< 12 months~2. Patients under chronic oral anticoagulation~3. Patients with proven allergy to aspirin, clopidogrel or ticagrelor~4. Patients that after TAVI cannot undergo a regimen of single or dual antiplatelet therapy for 3 months due to a new post-TAVI medical indication~5. Known pregnancy or breast-feeding~6. Concomitant oral or intravenous therapy with potent inhibitors of cytochrome P450 3A (CYP3A) that cannot be suspended during the course of the study. Medications considered as potent inhibitors are: ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin (or erythromycin but not astromicin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and more than a daily liter of grapefruit juice.~7. Thrombocytopenia (\<50,000 platelets U/L) well documented and clinically relevant.~8. Patients with documented moderate or severe hepatic insufficiency~9. Any condition that may put the patient at risk or influence the outcome of the trial~10. Patients previously randomized in this trial or in another clinical trial with an investigational product or device over the past 30 days.~11. Patients who cannot attend follow up visits scheduled in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: EXPERIMENTAL): Patients with high-on-treatment platelet reactivity (PRU ≥ 208)
- Aspirin/Clopidogrel (Type: ACTIVE_COMPARATOR): Patients with high-on-treatment platelet reactivity (PRU ≥ 208)
- Registry arm (Type: NO_INTERVENTION): Patients with normal-on-treatment platelet reactivity (PRU \< 208) will continue with Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent will be obtained before any study-related activities. Study-related activities are any data collection from the medical records of the patient~* Male or female age greater than or equal to 18 years at the time of insulin degludec initiation~* Type 1 diabetes mellitus or insulin-treated type 2 diabetes mellitus patients~* Switched to insulin degludec (± prandial insulin) after any basal insulin (± prandial insulin). Switch must have occurred at least 6 months prior to data collection and the patient may or may not be treated with insulin degludec at the time of patient selection~* Previously treated with any basal insulin (± prandial insulin) for at least 6 months prior to switching to insulin degludec~* At least one documented medical visit in the first 6 months (closest value in 3 to 9 months window) after insulin degludec initiation~* Minimum available data at the time of insulin degludec initiation: age, type of diabetes, HbA1c, duration of diabetes, duration and type of insulin treatment, medical follow-up at the study site for at least 1 year, and an estimated glomerular filtration rate (eGFR) value in the last 12 ±6 months (full data period)~Exclusion Criteria:~* Previous participation in this study. Participation is defined as having signed the Informed Consent in this study~* Patients treated by continuous subcutaneous insulin infusion or premix insulin in the 6 months prior to receiving Tresiba

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with diabetes (Type: None): Patients with type 1 diabetes and type 2 diabetes who received at least one prescription of insulin degludec (Tresiba®).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female pediatric patients of all ethnicities (age newborn to 6 years) with known or suspected CHD with inconclusive echocardiographic exams and are referred for cardiovascular MRI for further evaluation of cardiac anatomy and function.~* Written informed consent obtained from subject's legal representative/guardian(s) and ability for subject to comply with the requirements of the study~Exclusion Criteria:~* Standard clinical contraindications to MRI, including subjects with cochlear implants and implanted cardiac devices~* Subjects with past or current diagnosis of iron overload due to hereditary hemochromatosis or other causes (for subjects receiving Feraheme injection only).~* Subjects with known hypersensitivity or allergy to iron oxide particles.~* Subjects with renal insufficiency defined as estimated glomerular filtration rate (eGFR) \< 40 mL/min/1.73m2 (for subjects receiving Ablavar injection only).~* Subjects who are critically ill at the time of MRI and for whom the period of general anesthesia and separation from the critical care nursery or intensive care unit poses added risk as deemed by referring cardiologists, cardiac surgeons or the managing radiologist (for Part II only).~* Other medical conditions, in the judgment of the clinician investigator, that would increase the risks to the child related to participation in the study.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Ferumoxytol (Type: ACTIVE_COMPARATOR): Ferumoxytol, 4mg/kg of body weight, one time infusion of several minutes
- gadofosveset (Type: ACTIVE_COMPARATOR): gadofosveset, 0.03mmol/kg, one time bolus injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic confirmation of NSCLC.~* Patients have measurable or evaluable lesions based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.~* Unresectable phase IIIA(N2) and IIIB lung cancer confirmed by PET/CT, CT or MRI.~* Whole lung V20\>=35% when giving 60Gy which is the minimum dose of radical irradiation.~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.~* Previously treated with chemotherapy or treatment-naive~* No previous chest radiotherapy, immunotherapy or biotherapy~* Hemoglobin≥10 mg/dL, platelet≥100000/μL,absolute neutrophil count ≥1500/μL~* Serum creatinine ≤1.25 times the upper normal limit(UNL), or creatinine clearance≥60 ml/min~* Bilirubin ≤1.5 times UNL, AST（SGOT）≤2.5 times UNL ,ALT（SGPT）≤2.5 times UNL,alkaline phosphatase ≤5 times UNL~* FEV1 \>0.8 L~* CB6 within normal limits~* patients and their family signed the informed consents~Exclusion Criteria:~* Previous or recent another malignancy, except nonmelanoma skin cancer or cervical cancer in situ~* Contraindication for chemotherapy~* Malignant pleural or pericardial effusion.~* Women in pregnancy, lactation period, or no pregnancy test 14 days before the first dose~* Women who has the probability of pregnancy without contraception~* Tendency of hemorrhage~* In other clinical trials within 30 days~* Addicted in drugs or alcohol, AIDS patients~* Uncontrollable seizure or psychotic patients without self-control ability~* Severe allergy or idiosyncrasy~* Not suitable for this study judged by researchers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- split-course radiotherapy (Type: EXPERIMENTAL): The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to gross tumor. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is re-simulated. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Colonic or small bowel Crohn's disease based on endoscopic appearances and histology~* Refractory to induction with infliximab or adalimumab; or have lost response to these agents; or have had side effects precluding their further use~* Where there has been loss of response to one of these agents, the other must be tried before being eligible~* Crohn's disease activity score (CDAI) 250 or more.~* C-reactive protein \>10mg/L~* Surgery must have been offered to the subject (if appropriate) and declined~* Signed informed consent~Exclusion Criteria:~* Active sepsis, perforating disease. Coexistent perianal fistulous disease is permitted, providing no co-existent infection within previous 4 weeks~* Chronic stricturing disease in isolation~* Coexistent CMV disease~* Prior history of malignancy~* Pregnant or unwilling to practice contraceptive therapy or breast feeding females~* Last biologic therapy must be greater than 4 weeks prior, must be on stable corticosteroid dose for 14 days prior, during therapy and for 14 days after therapy, must be on stable immunomodulator dose (eg, azathioprine) for 14 days prior, during therapy and for 14 days after.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Mesenchymal stromal cells (Type: EXPERIMENTAL): Mesenchymal stromal cells administered weekly for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability and acceptance to provide written consent~* Men or women between 18-75 years~* Body Mass Index of ≥ 18 and ≤ 30 kg/m2~Exclusion Criteria:~* History (within the 12 months prior to screening) of psychiatric disorders~* Major surgery, trauma, illness or immobile for 3 or more days within the past month~* Pregnancy or recent pregnancy (within 6 weeks)~* A positive test for drugs of abuse at the screening visit~* Any other sound medical reason as determined by the clinical investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- tasimelteon (Type: EXPERIMENTAL): tasimelteon, administered as oral capsule(s)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, administered as oral capsule(s)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Are male or female participants with Type 1 Diabetes Mellitus (T1DM)~* Have a body mass index (BMI) of 18.5 to 30.0 kilogram per meter square (kg/m²)~* Have a glycated hemoglobin (HbA1c) less than (\<)9.0 percent (%)~* Have had no episodes of severe hypoglycaemia in the last 6 months~Exclusion Criteria:~* Have a history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (apart from T1DM), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data~* Have a history of renal impairment~* Have a history of deep vein thrombosis of the leg or repeated episodes of deep leg vein thrombosis in first-degree relatives~* Have proliferative retinopathy or maculopathy and/or severe neuropathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Elderly Adults LY900014 (Type: EXPERIMENTAL): Single, subcutaneous (SC) 15-U dose of LY900014 in the elderly adult group.
- Elderly Adults Insulin Lispro (Type: ACTIVE_COMPARATOR): Single, SC 15-U dose of insulin lispro (Humalog) in in the elderly adult group.
- Younger Adults LY900014 (Type: EXPERIMENTAL): Single, SC 15-U dose of LY900014 in the younger adult group.
- Younger Adults Insulin Lispro (Type: ACTIVE_COMPARATOR): Single, SC 15-U dose of insulin lispro (Humalog) in the younger adult group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* The duration of the index hospitalization must have been at least 3 and no more than 10 consecutive days~* Must meet venous thromboembolism (VTE) risk criteria with a total modified Improve VTE Risk Score of: greater than or equal 4, or 3 with D-dimer \> 2\* upper limit of normal (ULN), or 2 with D-dimer \> 2\*ULN~Key Exclusion Criteria:~* Any serious bleeding within 3 months prior to randomization or occurring during index hospitalization~* Serious trauma (including head trauma) within 4 weeks before randomization~* History of hemorrhagic stroke at any time in the past~* Any medical condition that requires chronic use of any parenteral or oral anticoagulation

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Each patient will receive either 10 mg or 7.5 mg rivaroxaban tablet once daily orally (by mouth) for 45 days. The dosing will depend on a creatinine clearance at screening.
- Placebo (Type: PLACEBO_COMPARATOR): Each patient will receive matching placebo tablet once daily orally (by mouth) for 45 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Recombinant Hepatitis E Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy people aged from 16 years to 65 years old at the time of the first vaccination, normal intelligence and agree to sign the informed consent form.~* Subjects will reside in the study region in the next 19 months.~* Free of history of hepatitis B or hepatitis E.~* Can comply with the request of study.~* Axillary temperature is below 37 degree centigrade.~Exclusion Criteria:~For dose 1:~* Having other vaccine or immunoglobulin within two weeks;~* Having allergic history to vaccine and medicine~* Eclampsia, epilepsy, encephalopathy and history of mental disease or family;~* Thrombocytopenia or other disturbance of blood coagulation which would lead to muscle injection taboo;~* Fixed or suspected deficiency of immunologic function, containing immunosuppressant treatment(radiation therapy, chemical treatment, steroid hormone, antimetabolites, cytotoxic drugs), genetic defect(e.g. fabism), HIV or other factors;~* congenital malformation, eccyliosis or severe chronic disease(e.g. Down Syndrome, diabetes, sickle cell anemia or mental disease);~* fixed or suspected other disease including fever, active infection, liver and kidney disease, angiocardiopathy, malignancy, acute and chronic disease;~* joining other clinical study undergoing;~* women pregnant or in lactation.~For dose 2 or 3:~* Severe allergy for dose 1 or 2;~* Severe adverse reaction associated with last vaccination;~* New occurrence of symptoms meet dose 1 exclusion criteria after the first dose.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Hepatitis E vaccine (Type: EXPERIMENTAL): Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
- HBV vaccine (Type: PLACEBO_COMPARATOR): Hepatitis B vaccine, containing 5mcg of HBsAg recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is male or female ≥35 years of age to ≤75 years of age at the time of enrollment.~* Subject has idiopathic Parkinson's disease consistent with the UK Brain Bank Criteria; must have bradykinesia with sequence effect and rest tremor or prominent motor asymmetry.~* Subject with disease duration no longer than 3 years and 0 months.~* Subject has a Hoehn \& Yahr (H\&Y) stage score of \< 3.~* Subject has a MMSE score ≥ 26~Exclusion Criteria:~* Subject has an atypical parkinsonian syndrome or secondary parkinsonism (e.g., due to drugs, metabolic neurogenetic disorders, encephalitis, cerebrovascular disease or degenerative disease).~* Subject has a history of psychosis or hallucinations within the previous 12 months.~* Subject who is taking anticholinergic drugs.~* Subject has previous exposure to levodopa or a dopamine agonist for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 2 months prior to the baseline visit.~* Subject has previous exposure to a MAO-B inhibitor for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 3 months prior to the baseline visit.~* Subject who is taking MAO inhibitors, potent CYP1A2 inhibitors, e,g, Ciprofloxacin, Dextromethorphan or antitussive agent, analgesic agents such as tramadol, meperidine, methadone and propoxyphene, strong 3A4 inducers, e.g., St. John's Wort or cyclobenzaprine (tricyclic muscle relaxant), dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide. Probenecid, cimetidine, ranitidine, diltiazem, verapamil and quinidine.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg), (Type: EXPERIMENTAL): Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily.
- P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg), (Type: EXPERIMENTAL): Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete